A New Scale for Evaluating Disability in Multiple Sclerosis

Kurtzke, John F.

doi:10.1212/wnl.5.8.580

Cited by 277 publications

(168 citation statements)

References 0 publications

Supporting

Mentioning

156

Contrasting

Unclassified

Order By: Relevance

“…Therefore, these 4 patients were excluded, and 20 patients (5 men and 15 women; mean age, 46.7 years; age range, 31-67 years) were included in the analysis. The median Expanded Disability Status Scale (EDSS) score 22 at imaging was 1.3 (range, 0 -7), and the mean disease duration was 11.5 Ϯ 7.5 years. The institutional review board of Juntendo University Hospital approved this study, and written informed consent was obtained from all participants.…”

Section: Study Participantsmentioning

confidence: 99%

Analysis of White Matter Damage in Patients with Multiple Sclerosis via a Novel In Vivo MR Method for Measuring Myelin, Axons, and G-Ratio

Hagiwara¹,

Hori²,

Yokoyama

et al. 2017

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

show abstract

Section: Study Participantsmentioning

confidence: 99%

Analysis of White Matter Damage in Patients with Multiple Sclerosis via a Novel In Vivo MR Method for Measuring Myelin, Axons, and G-Ratio

Hagiwara¹,

Hori²,

Yokoyama

et al. 2017

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

show abstract

“…Patients provided information on: age, sex, living arrangements, educational level, employment status, and informal caregiver(s). Disease information including year of diagnosis, year of first symptoms, type of MS, disability (captured using the self-administered Expanded Disability Status Scale (EDSS) 24 ), comorbidities (arthritis, osteoporosis, depression, anxiety, sleep disorders, hypertension and urinary tract infections/incontinence) and treatment with disease modifying drugs (DMDs) was also captured. The disability scale version used in the study was the modified and validated version that had been previously used in other cost-of-illness studies in MS 20 .…”

Section: Assessmentsmentioning

confidence: 99%

ENCOMS: Argentinian survey in cost of illness and unmet needs in multiple sclerosis

Ysrraelit

Cáceres²,

Villa³

et al. 2014

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

The objective of the study was to assess the cost of multiple sclerosis (MS) patients in Argentina categorized by disease severity using a societal perspective. Method: Cross-sectional study including MS patients from 21 MS centers in 12 cities of Argentina. Patients were stratified by disease severity using the expanded disability status scale (EDSS) (group 1 with EDSS score between 0 and 3; group 2 with EDSS .3 and ,7; group 3 with EDSS $7). Direct and indirect costs were analyzed for the second quarter of 2012 from public sources and converted to US Dollars. Results: 266 patients were included. Mean annual cost per MS patient was USD 36,025 (95%CI 31,985-38,068) forts patients with an EDSS between 0-3; USD 40,705 (95%CI 37,300) for patients with EDSS .3 and ,7, and USD 50,712 (95%CI 47,825-62,104) for patients with EDSS $7. Conclusions: This is the first Argentine study evaluating the costs of MS considering disease severity.Keywords: multiple sclerosis, costs, cost-of-illness, Argentina, Latin America. RESUMOEl objetivo del estudio fue evaluar el costo de los pacientes con esclerosis múltiple (EM) en Argentina categorizados por severidad de la enfermedad. Método: Estudio de corte transversal que incluyó pacientes con EM en 12 ciudades de Argentina. Los pacientes se estratificaron según expanded disability status scale (EDSS) (grupo 1 EDSS entre 0 y 3; grupo 2 EDDS .3 y ,7; grupo 3 EDSS $7). Los costos directos e indirectos fueron analizados para el segundo trimestre de 2012 y convertidos a dólares estadounidenses. Resultados: 266 pacientes fueron incluidos. El coste medio anual por paciente con EM fue de USD 36,025 (31,985-38,068 IC95%) para los pacientes con un EDSS entre 0-3; USD 40,705 (37,,300 IC95%) para los pacientes con EDSS .3 y ,7 y USD 50,712 (47,825-62,104 IC95%) para los pacientes con EDSS $7. Conclusiones: Primer estudio argentino evaluar los costes de la EM considerado la gravedad de la enfermedad.Palavras-chave: esclerosis múltiple, costos, enfermedad, Argentina, Latino-América.

show abstract

“…This is due to weakness, spasticity, balance problems and/or fatigue alone or in any combination [2]. A recent report indicates that, for those with relapse-remitting MS, the median time from diagnosis to requiring a wheelchair for mobility is 28 years [3], as measured by the Disability Status Scale (DSS) for MS [4] where a score of eight is defined as ''essentially restricted to bed or chair or perambulated in wheelchair, but may be out of bed itself much of the day; retains many self-care functions; generally has effective use of arms''. This group of people with MS (PwMS) are the most likely to benefit from the provision of powered mobility and it has been estimated from a Canadian survey, that approximately 8% of people with MS (PwMS) will use powered wheelchairs [5].…”

Section: Introductionmentioning

confidence: 99%

Problematic clinical features of powered wheelchair users with severely disabling multiple sclerosis

Souza

Frank

2014

Disability and Rehabilitation

View full text Add to dashboard Cite

Purpose: The aim of this study is to describe the clinical features of powered wheelchair users with severely disabling multiple sclerosis (MS) and explore the problematic clinical features influencing prescription. Method: Retrospective review of electronic and case note records of recipients of electric-powered indoor/outdoor powered wheelchairs (EPIOCs) attending a specialist wheelchair service between June 2007 and September 2008. Records were reviewed by a consultant in rehabilitation medicine, data systematically extracted and entered into a computer database. Further data were entered from clinical records. Data were extracted under three themes; demographic, diagnostic, clinical and wheelchair factors. Results: Records of 28 men mean age 57 (range 37-78, SD 12) years and 63 women mean age 57 (range 35-81, SD 11) years with MS were reviewed a mean of 64 (range 0-131) months after receiving their wheelchair. Twenty two comorbidities, 11 features of MS and 8 features of disability were thought to influence wheelchair prescription. Fifteen users were provided with specialised seating and 46 with tilt-in-space seats. Conclusions: Our findings suggest that people with severe MS requiring an EPIOC benefit from a holistic assessment to identify problematic clinical features that influence the prescription of the EPIOC and further medical and therapeutic interventions. ä Implications for RehabilitationPeople with multiple sclerosis (MS), referred for an EPIOC, require a full clinical assessment to identify problematic clinical features that are potentially treatable and/or can be accommodated through specialised seating and tilt. The beneficial effects of TIS should be considered for all EPIOC users with MS and particularly for those with comorbidity Poorly controlled spasticity, when identified in people with MS, should be managed through positioning in the chair, pressure-relieving cushion and referral for medical management.

show abstract

A New Scale for Evaluating Disability in Multiple Sclerosis

Cited by 277 publications

References 0 publications

Analysis of White Matter Damage in Patients with Multiple Sclerosis via a Novel In Vivo MR Method for Measuring Myelin, Axons, and G-Ratio

Analysis of White Matter Damage in Patients with Multiple Sclerosis via a Novel In Vivo MR Method for Measuring Myelin, Axons, and G-Ratio

ENCOMS: Argentinian survey in cost of illness and unmet needs in multiple sclerosis

Problematic clinical features of powered wheelchair users with severely disabling multiple sclerosis

Contact Info

Product

Resources

About